How to buy Bristol-Myers Squibb Company stock

Bristol-Myers Squibb Company is a drug manufacturers-general business based in the US. Bristol-Myers Squibb Company shares (BMY) are listed on the NYSE and all prices are listed in US Dollars. Bristol-Myers Squibb Company employs 30,250 staff and has a trailing 12-month revenue of around 0.00.

Bristol-Myers Squibb Company share price

Use our graph to track the performance of BMY stocks over time.

Bristol-Myers Squibb Company shares at a glance

• Key figures

Information last updated 2021-05-07.

52-week range	$52.43 - $66.93
50-day moving average	$63.87
200-day moving average	$62.39
Wall St. target price	$75.44
PE ratio	N/A
Dividend yield	$1.88 (2.92%)
Earnings per share (TTM)	$0.51

Buy Bristol-Myers Squibb Company shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Bristol-Myers Squibb Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Bristol-Myers Squibb Company by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Bristol-Myers Squibb Company under- or over-valued?

Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bristol-Myers Squibb Company's PEG ratio

Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 22.1838. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bristol-Myers Squibb Company's EBITDA

Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.3 billion.

The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.

Bristol-Myers Squibb Company financials

Revenue TTM	$42.8 billion
Operating margin TTM	17.74%
Gross profit TTM	$34 billion
Return on assets TTM	3.93%
Return on equity TTM	-14.15%
Profit margin	-14.53%
Book value	$16.84
Market capitalisation	$144 billion

TTM: trailing 12 months

Shorting Bristol-Myers Squibb Company shares

There are currently 19.0 million Bristol-Myers Squibb Company shares held short by investors – that's known as Bristol-Myers Squibb Company's "short interest". This figure is 24.6% down from 25.2 million last month.

There are a few different ways that this level of interest in shorting Bristol-Myers Squibb Company shares can be evaluated.

Bristol-Myers Squibb Company's "short interest ratio" (SIR)

Bristol-Myers Squibb Company's "short interest ratio" (SIR) is the quantity of Bristol-Myers Squibb Company shares currently shorted divided by the average quantity of Bristol-Myers Squibb Company shares traded daily (recently around 11.6 million). Bristol-Myers Squibb Company's SIR currently stands at 1.63. In other words for every 100,000 Bristol-Myers Squibb Company shares traded daily on the market, roughly 1630 shares are currently held short.

However Bristol-Myers Squibb Company's short interest can also be evaluated against the total number of Bristol-Myers Squibb Company shares, or, against the total number of tradable Bristol-Myers Squibb Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bristol-Myers Squibb Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bristol-Myers Squibb Company shares in existence, roughly 10 shares are currently held short) or 0.0085% of the tradable shares (for every 100,000 tradable Bristol-Myers Squibb Company shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bristol-Myers Squibb Company.

Find out more about how you can short Bristol-Myers Squibb Company stock.

Bristol-Myers Squibb Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Bristol-Myers Squibb Company's total ESG risk score

Total ESG risk: 29.16

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Bristol-Myers Squibb Company's environmental score

Environmental score: 3.83/100

Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's social score

Social score: 18.82/100

Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Bristol-Myers Squibb Company's governance score

Governance score: 14.02/100

Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.

Total ESG score	29.16
Total ESG percentile	52.58
Environmental score	3.83
Environmental score percentile	4
Social score	18.82
Social score percentile	4
Governance score	14.02
Governance score percentile	4
Level of controversy	2

Bristol-Myers Squibb Company share dividends

Dividend payout ratio: 29.1% of net profits

Recently Bristol-Myers Squibb Company has paid out, on average, around 29.1% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.03% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 3.03% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $1.88 per share.

While Bristol-Myers Squibb Company's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb Company may be investing much of the rest of its net profits in future growth.

Bristol-Myers Squibb Company's most recent dividend payout was on 2 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 30 March 2021 (the "ex-dividend date").

Have Bristol-Myers Squibb Company's shares ever split?

Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.

Bristol-Myers Squibb Company share price volatility

Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as $52.4297 up to $66.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.6198. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).

Bristol-Myers Squibb Company overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.

Frequently asked questions

• What percentage of Bristol-Myers Squibb Company is owned by insiders or institutions?

  Currently 0.07% of Bristol-Myers Squibb Company shares are held by insiders and 76.739% by institutions.

• How many people work for Bristol-Myers Squibb Company?

  Latest data suggests 30,250 work at Bristol-Myers Squibb Company.

• When does the fiscal year end for Bristol-Myers Squibb Company?

  Bristol-Myers Squibb Company's fiscal year ends in December.

• Where is Bristol-Myers Squibb Company based?

  Bristol-Myers Squibb Company's address is: 430 East 29th Street, New York, NY, United States, 10016

• What is Bristol-Myers Squibb Company's ISIN number?

  Bristol-Myers Squibb Company's international securities identification number is: US1101221083

• What is Bristol-Myers Squibb Company's CUSIP number?

  Bristol-Myers Squibb Company's Committee on Uniform Securities Identification Procedures number is: 110122108